Cover Image

Bosque, Brandon A; Frampton, Christopher; Chaffin, Abigail E.; Bohn, Gregory; Woo, Kevin; DeLeonardis, Candace; Lepow, Brian; Melin, M. Mark; Madu, Tobe; Dowling, Shane G.; May, Barnaby C. H.

doi:10.1111/iwj.13813

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median time for wound healing is faster in OFM groups, which is 14.6±0.5 weeks as compared to the collage/ORC group, 16.4 ± 0.7 weeks. [ 79 ] Bio‐ConneKt is another FDA‐approved chemically cross‐linked wound matrix. It is made up of reconstituted type‐I collagen that is obtained from the equine (horse) tendon.…”

Section: Commercial Products For Chronic Wounds Treatmentmentioning

confidence: 99%

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Sharma

Zhao

2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Impaired wound healing after trauma, disorders, and surgeries impact millions of people globally every year. Dysregulation in orchestrated healing mechanisms and underlying medical complications make chronic wound management extremely challenging. Besides standard‐of‐care treatments including broad spectrum antibiotics and wound‐debridement, novel adjuvant therapies are clinically tested and commercialized. These include topical agents, skin substitutes, growth factor delivery, and stem cell therapies. With a goal to overcome factors playing pivotal role in delayed wound healing, researchers are exploring novel approaches to elicit desirable healing outcomes in chronic wounds. Although recent innovations in wound care products, therapies, and devices are extensively reviewed in past, a comprehensive review summarizing their clinical outcomes is surprisingly lacking. Herein, this work reviews the commercially available wound care products and their performance in clinical trials to provide a statistically comprehensive understanding of their safety and efficacy. The performance and suitability of various commercial wound care platforms, including xenogeneic and allogenic products, wound care devices, and novel biomaterials, are discussed for chronic wounds. The current clinical evaluation will provide a comprehensive understanding of the benefits and drawbacks of the most‐recent approaches and will enable researchers and healthcare providers to develop next‐generation technologies for chronic wound management.

show abstract

Section: Commercial Products For Chronic Wounds Treatmentmentioning

confidence: 99%